In this report we have demonstrated that TAK-659 is able to effectively impair CLL cell migration toward CXCL12, CXCL13 and the BMSC cell line HS-5, in line with previous studies with other BCR inhibitors [37, 38]. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.